For treatment options call 1-866-830-4576 | Scottsdale, AZ
Precision Genomic Analysis
for Your Cancer Treatment
is Just One Call Away Call Now Envita Medical Centers building

Envita’s Advanced Genomic Analysis Provides Cancer Patients with Targeted Treatment Options

For the last 25 years, Envita Medical Centers in Scottsdale, Arizona has been innovating in the field of genomic analysis to establish targeted treatment options at the cancer’s cellular level, regardless of the tumor type or stage.

This personalized and in-depth analysis helps our expert medical team identify and fix the disruptions at the core of your cancer, disruptions that can promote the growth and spread of disease. We don’t just manage your disease but aim to shut it down with the goal of improving quality of life, increasing longevity, and reducing toxicity.

At Envita, we take precision to the next level by offering patient-specific oncology options for all our patients, unlike standard oncology where only 20% or fewer patients get access to precision options.

Depth of Precision Oncology graph

Why Genomic Identification is Crucial in Cancer Treatment?

In our clinical opinion, we have demonstrated time and again how genomic identification forms the bedrock of a precision targeted cancer treatment, minimizing the chances of multidrug resistance (MDR) and a weakened immune system, which often leads to cancer metastasis or recurrence. We custom design a unique medical blueprint for each individual patient based on an in-depth genomic identification. This blueprint establishes a targeted approach to care as opposed to administering standard treatments based on a patient’s tumor type and stage. A personalized treatment plan is designed to attack each patient’s specific cancer from all possible angles, giving them an edge over their cancer.

Genomic Analysis to Decode Cancer Triggers

When cells grow old or become damaged, they die a natural death, this process is called apoptosis, but a disruption in this process may trigger genetic mutations, potentially causing cancer. To treat cancer at its root, it is crucial to examine the patient’s molecular cell biology using an extensive genomic analysis. This in-depth analysis investigates the genomics, transcriptomics, proteomics, and metabolomics of a cell, to proactively treat your cancer.

Recurrence Estimates of Cancers Following Standard Oncology Treatment

  1. Cancer Type Bladder
  2. Recurrence Rate 50% after cystectomy
  1. Cancer Type Breast
  2. Recurrence Rate 50% after cystectomy
  1. Cancer Type Colorectal
  2. Recurrence Rate 17% after curative surgical resection with microscopically clear margins
  1. Cancer Type Head and neck, stage IV
  2. Recurrence Rate After intensified, split-course, hyperfractionated multiagent chemoradiotherapy: 17%, locoregional 22%, distant
  1. Cancer Type Hodgkin lymphoma
  2. Recurrence Rate 10% to 13% after primary treatment; 20% to 50% after second-line treatment
  1. Cancer Type Kidney
  2. Recurrence Rate 13%; 49% after complete response to tyrosine kinase inhibitor therapy
  1. Cancer Type Lymphoma, DLBCL (diffuse large B-cell lymphoma)
  2. Recurrence Rate 30% to 40%
  1. Cancer Type Lymphoma, PTCL (peripheral T-cell lymphoma)
  2. Recurrence Rate 75%
  1. Cancer Type Melanoma
  2. Recurrence Rate 15% to 41%, depending on stage; 87%, metastatic disease
  1. Cancer Type NSCLC (non-small cell lung cancer)
  2. Recurrence Rate 26% after curative surgery; 27% after chemoradiotherapy for locally advanced disease
  1. Cancer Type Osteosarcoma
  2. Recurrence Rate 11%-12% local recurrence; 5%-45% metastasis
  1. Cancer Type Ovarian
  2. Recurrence Rate 85%
  1. Cancer Type Pancreas
  2. Recurrence Rate 36% within 1 year after curative surgery; 38% local recurrence after adjuvant chemotherapy; 46% distant metastasis after adjuvant chemotherapy
  1. Cancer Type Prostate
  2. Recurrence Rate After prostatectomy at 10 years: 24% low-risk disease; 40% intermediate-risk disease; 48% high-risk disease;
  1. Cancer Type Soft tissue sarcoma
  2. Recurrence Rate 50% after adjuvant chemotherapy; Nearly 100% for advanced disease;
  1. Cancer Type Thyroid
  2. Recurrence Rate Up to 30% for differentiated thyroid carcinoma; 8%-14% after surgery for medullary thyroid carcinoma;

DNA-Gene Genomics

DNA alterations can affect the structure, function, and amount of the corresponding proteins produced by the cell.

These changes can impact a cell’s behavior, making it cancerous. Analyzing these changes helps us gauge several facets of your specific cancer, allowing us to personalize your treatment, targeting your specific cancer biomarkers. Biomarkers are attributes of your specific cancer cell that provide valuable information to help direct treatment.

miRNA Transcriptomics

Transcriptomics is the study of transcriptomes (all RNAs in a living being) and their functions.

MiRNA (MicroRNA) is a non-coding RNA molecule that functions in a wide range of mechanisms to increase or decrease the production specific proteins or RNA. In cancer cells, the balance between miRNAs which includes tumor suppressor genes and oncogenes, is affected, causing uncontrolled growth of the cell. We analyze the miRNA and examine intricate details of your cell biology to select therapies to get your miRNA working properly. These therapies can help in reducing chances of recurrence or spread of cancer.

Protein Proteomics

Proteomics is the study of proteins synthesized by the cells.

Cancer proteomics involves the identification and quantitative analysis of differentially expressed proteins, as compared to healthy tissue counterparts at different stages of disease. Examining these proteins complement the detailed analysis of genomics and transcriptomics, helping in better understanding of the cancer cell physiology.

Metabolite Metabolomics

Metabolomics is the study of metabolites which provide pathways and signaling information for targeted treatment delivery.

It also helps us understand intrinsic factors like genomic alterations and extrinsic factors like nutrients, drugs, hormones, adjuvants, and the immune system which contribute to the metabolic reprogramming of cancer cells. These factors are important for integrative adjuvant care to be most effective.*
* Schmidt, D. R., Patel, R., Kirsch, D. G., Lewis, C. A., Vander Heiden, M. G., & Locasale, J. W. (2021). Metabolomics in cancer research and emerging applications in clinical oncology. CA: a cancer journal for clinicians, 71(4), 333–358.

Targeting the Vicious Ecosystem of Cancer (Altered Gene Accumulation)

A complex interplay of abnormally functioning genomes, transcriptomes, proteins, and metabolites leads to an altered gene accumulation, which in turn creates a vicious ecosystem, causing further proliferation. Our extensive genomic analysis helps us identify with precision the drivers of the cancer and build a comprehensive treatment strategy, focused on addressing key factors in the development and circulation of cancer.

Following are some of the key factors in cancer growth and spread:

Understanding Your Cancer’s Microenvironment

When your cancer cells grow uncontrollably, they may accumulate together forming a lump in your tissue, which is a tumor. Once a tumor reaches 2mm in diameter, it can no longer sustain itself and the cells within the tumor begin to produce a signaling protein, known as vascular endothelial growth factor (VEGF). This growth factor stimulates the physiological process of angiogenesis, which is the formation of new, irregular blood vessels around the tumor to feed it.

With the blood supply to feed it, a tumor can grow exponentially. It eventually breaks and the tiny circulating tumor cells (CTCs) travel through the blood vessels to different parts of the body, spreading the cancer. This process is called metastasis, which is the primary cause of cancer deaths.*

*Seyfried, T. N., & Huysentruyt, L. C. (2013). On the origin of cancer metastasis. Critical reviews in oncogenesis, 18(1-2), 43–73.

Cancer cell growing

How we tackle it

Envita’s personalized treatment protocols, built on each patient’s genomic analysis, work to decelerate, or prevent metastasis by addressing the microenvironment around your cancer. Our doctors can utilize antiangiogenic smart drug technology, alongside customized integrative medicines, to silence cancerous blood vessel growth, thereby slowing the spread of circulating cancer cells. Combining genetic targets and natural agents with comprehensive and highly detailed testing allows for customized medication that focuses on the patient’s specific needs, making all the difference in care.

Microsatellite Instability

Microsatellite instabilities (MSI) are defined as, “A change that occurs in certain cells (such as cancer cells) in which the number of repeated DNA bases in a microsatellite (a short, repeated sequence of DNA) is different from what it was when the microsatellite was inherited.” In other words, MSI are thought to be the result of mutations that do not get corrected when DNA is copied inside of a cell. This allows for the continued mutation of the cancerous cells, making treatment extremely difficult because of constantly changing targets.

Fixing broken DNA Replicating broken DNA

How we tackle it

Our in-depth genomic analysis helps to accurately measure the rate of these changes so we can deploy the correct treatments to slow them down. Accurately targeting your cancer is crucial because mutational rates can be worsened by the wrong chemotherapy selection.

Overcoming the mutational rate of the cancer is essential to improving outcomes and impacting the cancer. At Envita, we understand that last month’s cancer is not today’s cancer, so we have developed treatments to address each patient’s specific microsatellite instability in real time, which helps to keep them one step ahead of their disease.

Epigenetic Influences on Mutation

Unlike genetic changes, epigenetic changes are reversible and do not change your DNA sequence, but they can change how your body reads a DNA sequence. Epigenetic influences can cause mutations in proto-oncogenes, genes that normally help cells grow. Mutated proto-oncogenes are called oncogenes, which are a type of miRNA.

Increased levels of oncogenes in a cell can push down the levels of tumor suppressor genes, which is another type of miRNA. Tumor suppressor genes, as the name implies, are genes that slow down cell division and repair DNA mistakes. They are also responsible for signaling apoptosis or programmed cell death.

Epigenetic Influences on Mutation

Metastasis and tumor growth have been highly correlated with loss of tumor suppressor and oncogene regulation.* Cancerous cells have an abnormal balance of tumor suppression and oncogene expression.* Normally the body uses these genes to regulate cell division and death. When this balance is disturbed, cancerous cells can form. In time, these cells will work to gain a blood supply through the angiogenesis process and begin spreading throughout the body. If miRNA is not addressed in treatment as soon as possible, the cancer can spread and become more and more difficult to treat.

*Levine, A. J., & Puzio-Kuter, A. M. (2010). The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science (New York, N.Y.), 330(6009), 1340–1344.

*Lodish H, B.A., Zipursky SL, Proto-Oncogenes and Tumor Suppressor Genes.

How we tackle it

There are thousands of different miRNA variations and Envita’s extensive genomic analysis allows for identification of miRNA targets through next-generation DNA sequencing.

Our customized algorithm helps us precision target the most recent mutations of each patient’s individual cancer.

Combined with customized integrative medications, Envita’s unique precision treatment protocols aim to aggressively downregulate oncogenes and upregulate tumor suppressor genes. This miRNA gene silencing therapy may initiate the body's natural defense against cancerous cells and possibly halt the growth and spread of the disease.

Controlling the growth and spread of the disease, as we shut down its drivers are the hallmarks of Envita’s Personalized Precision Oncology. Our extensive genomic analysis serves as the best tool that can be used to uncover each patient’s specific cancer drivers. Knowing these factors help us design a personalized, precision-targeted treatment plan, which aims at benefitting patients in their journey of holistic recovery.

Envita’s Ultra Analytes Liquid Biopsy goes far beyond genomics to include immunotherapy and root causes of the cancer. With less than 20% of all cancer patients getting watered down version of precision genomics, Envita provides next-level planning and detailed development to help you outperform.

Envita Precision Algorithm vs.
Standard Oncology Precision Testing

RNA Transcriptome Genes
Envita Medical Centers: 20,000+
Standard Oncology: Unchecked
SNV/CNV Genes
Envita Medical Centers: 452
Standard Oncology: 309
Rearrangements/Fusion Genes
Envita Medical Centers: 51
Standard Oncology: 27
Microsatellite Instability (MSI)
Envita Medical Centers: Checked
Standard Oncology: Checked
Tumor Mutation Burden (TMB)
Envita Medical Centers: Checked
Standard Oncology: Checked
BRCA 1/2
Envita Medical Centers: Checked
Standard Oncology: Checked
Immunohistochemistry
Envita Medical Centers: Checked
Standard Oncology: Unchecked
Chemosensitivity
Envita Medical Centers: Checked
Standard Oncology: Unchecked
Concurrent Liquid Biopsy
Envita Medical Centers: Checked
Standard Oncology: Unchecked
Exosomal miRNA Analysis
Envita Medical Centers: Checked
Standard Oncology: Unchecked
Circulating Tumor Cells Enumeration
Envita Medical Centers: Checked
Standard Oncology: Unchecked
Pharmacogenomics
Envita Medical Centers: Checked
Standard Oncology: Unchecked
Individualized Therapy Recommendation
Envita Medical Centers: Checked
Standard Oncology: Unchecked
Carcinogenic Exposure - Root Causes
Envita Medical Centers: Checked
Standard Oncology: Unchecked
Inflammation Markers
Envita Medical Centers: Checked
Standard Oncology: Unchecked
Metabolic Target Drivers
Envita Medical Centers: Checked
Standard Oncology: Unchecked

*Individual results may vary. Envita makes no guarantees for outcomes.

Call Us Today If You Need Assistance, We Are Here to Help

Our specialized team including oncologists, interventional radiologists, researchers, and pharmacists leave no stone unturned to help you gain an edge over your cancer. They relentlessly work to personalize every aspect of your treatment to enhance efficacy and optimize results from over 25 years of helping patients. If you or your loved ones have any question regarding cancer, please feel free to call us at 866-830-4576 and may God bless you on your journey to healing.

Envita Patient Care Coordinator Samantha

Speak With a Patient Care Expert Now!

Choose Envita Medical Centers

Our team is ready to help you get your life back! Please enter your contact information and a Patient Care Expert will contact you shortly. If you would rather speak now, please give us a call at 1-866-830-4576 .

Please fill out your first name.
Please fill out your last name.
Please fill out your phone number.
Please fill out your email address.
Please make a selection.
Please make a selection.
You may request a call back from 8am-5pm Pacific Time. We cannot guarantee that you will receive a callback during your requested time, but we will do our best to contact you as soon as possible.
Please make a selection.
Please make a selection.
Please make a selection.
Max. 1000 characters. Do not include any web urls.
Please fill out your inquiry.

Latest Envita Reviews